Safety and biomarker assessment of ST316, a novel peptide antagonist of ß-catenin, in patients with advanced solid tumors.

MLA

El-Khoueiry, Anthony B., et al. “Safety and Biomarker Assessment of ST316, a Novel Peptide Antagonist of ß-Catenin, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology, vol. 43, Feb. 2025, p. 286. EBSCOhost, https://doi.org/10.1200/JCO.2025.43.4_suppl.286.

APA

El-Khoueiry, A. B., Lakhani, N. J., Henry, J. T., Powell, S. F., Mettu, N. B., Gakuria, J., Abbate, F., Nuciforo, P., Rotolo, J., & Vainstein Haras, A. (2025). Safety and biomarker assessment of ST316, a novel peptide antagonist of ß-catenin, in patients with advanced solid tumors. Journal of Clinical Oncology, 43, 286. https://doi.org/10.1200/JCO.2025.43.4_suppl.286

Chicago

El-Khoueiry, Anthony B., Nehal J. Lakhani, Jason Timothy Henry, Steven Francis Powell, Niharika B. Mettu, Joyce Gakuria, Franco Abbate, Paolo Nuciforo, Jim Rotolo, and Abi Vainstein Haras. 2025. “Safety and Biomarker Assessment of ST316, a Novel Peptide Antagonist of ß-Catenin, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology 43 (February): 286. doi:10.1200/JCO.2025.43.4_suppl.286.